Disparities in Access to Spasticity Chemodenervation Specialists in the United States: a National Analysis of Medicare Data
Objective: To explore the variations in access to spasticity chemodenervation specialists across several geographical, ethnic, racial, and population density factors. Background: Equity in access to…Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects
Objective: To confirm the efficacy and safety of incobotulinumtoxinA (INCO; Xeomin®, Merz Pharmaceuticals GmbH) in East Asian subjects from study sites in Japan with post-stroke…Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update – 29 Years of Safety Observation
Objective: The present study evaluated pregnancy outcomes following onabotulinumtoxinA exposure to provide a cumulative 29-year safety update. Background: A previous publication of pregnancy outcomes in…Management of Cervical Dystonia & Spastic Paresis with Botulinum Neurotoxin-A: results from the INPUT survey
Objective: To describe current practices among physicians using botulinum toxin-A (BoNT-A) to treat spastic paresis (SP) and cervical dystonia (CD). Background: BoNT-A is an effective…Multi-level and multi-pattern lower- and upper-limb spasticity treatment with incobotulinumtoxinA in children and adolescents with cerebral palsy
Objective: Assess efficacy and safety of incobotulinumtoxinA in lower-limb (LL) or combined LL/upper-limb (LL/UL) spasticity in children and adolescents with cerebral palsy (CP). Background: Ambulant…Phenotyping spasticity-associated tonic spasms: implications for therapy
Objective: To evaluate common phenotypes of tonic spasms (TS) in patients with spasticity and inform therapeutic interventions. Background: Spasticity can be associated with several hyperkinetic…Treatment with Botulinum Toxin for Refractory Fever caused by Severe Spasticity
Objective: Present a series of cases of patients with refractory fever associated to spasticity secondary to a brain or spinal cord injury who developed refractory…Identification of Factors that Impact Adherence to OnabotulinumtoxinA Treatment for Spasticity in Post-Stroke and Multiple Sclerosis Patients from ASPIRE
Objective: Identify baseline clinical characteristics and treatment-related factors that impact adherence to onabotulinumtoxinA (onabotA) treatment in post-stroke and multiple sclerosis (MS) patients from the Adult…Perceptions of burden of spasticity and treatment satisfaction among post-stroke patients over the course of a botulinum neurotoxin A (BoNT-A) treatment cycle: An ethnographic study
Objective: To design an ethnographic study following patients over a botulinum toxin type-A (BoNT-A) treatment cycle to inform individualized treatment. Background: The concept of individualized…High Dose Botulinum Toxin Therapy: Safety, Benefit and Endurance of Efficacy
Objective: To assess safety, therapeutic response and long-term benefit of higher dose Onabotulinum toxin A (OnaA). Background: Botulinum toxin therapy is a powerful tool for…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.